NBIX
NEUROCRINE BIOSCIENCES INC
Next earnings Jul 28, 2026 · consensus $1.61 EPS, $884M rev
Last earnings +0.7% on 2026-05-05
$167.82
▲ +1.06%$167.82▲ +31.82%
over 1Y
L $123.10EODHDH $167.82
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+1.1%
1W+4.4%
1M+6.6%
3M+26.6%
YTD+18.1%
1Y+30.4%
Buy
Conviction
Horizon
Long (>12mo)
12-mo target
$•••
Street · 36 analysts
Buy
Profitable neuroscience pharma compounding 20%+, INGREZZA cash cow plus CRENESSITY launch and a deep late-stage pipeline, at a reasonable 33.9x.
Sources: SEC EDGAR (CIK 0000914475, latest 10-Q filed 2026-05-05) · EODHD · analysis by claude-code · as of 6/21/2026, 8:43:57 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.